Literature DB >> 20168044

The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice.

Sei Higuchi1, Keiichi Irie, Shohei Mishima, Maiko Araki, Makiko Ohji, Atsunori Shirakawa, Yoshiharu Akitake, Kiyoshi Matsuyama, Kenji Mishima, Kenichi Mishima, Katsunori Iwasaki, Michihiro Fujiwara.   

Abstract

Endocannabinoids have been shown to activate reward-related feeding and to promote astrocytic differentiation. We investigated whether high-fat diet (HFD) intake produced a preference for HFD via an endocannabinoid-dependent mechanism. In the conditioned place preference test, the 2-week HFD-intake group showed preference for HFD and had increased expression of a marker for reactive astrocytes, glial fibrillary acid protein (GFAP), in the hypothalamus. The cannabinoid CB(1)-receptor antagonist O-2050 reduced the preference for HFD and expression of GFAP in the hypothalamus. These results suggested that HFD intake led to the development of a preference for HFD via astrocytic CB(1) receptors in the hypothalamus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20168044     DOI: 10.1254/jphs.09326sc

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  11 in total

1.  Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion.

Authors:  M López-Gallardo; A B López-Rodríguez; Á Llorente-Berzal; D Rotllant; K Mackie; A Armario; R Nadal; M-P Viveros
Journal:  Neuroscience       Date:  2011-10-06       Impact factor: 3.590

2.  Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Authors:  Jenny L Wiley; Christopher S Breivogel; Anu Mahadevan; Roger G Pertwee; Maria Grazia Cascio; Daniele Bolognini; John W Huffman; D Matthew Walentiny; Robert E Vann; Raj K Razdan; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2010-11-27       Impact factor: 4.432

3.  A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.

Authors:  Nicole P Bowles; Ilia N Karatsoreos; Xiaosong Li; V Kiran Vemuri; Jodi-Anne Wood; Zhiying Li; Kellie L K Tamashiro; Gary J Schwartz; Alexandros M Makriyannis; George Kunos; Cecilia J Hillard; Bruce S McEwen; Matthew N Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 4.  The Endocannabinoid System and Eating Behaviours: a Review of the Current State of the Evidence.

Authors:  Nathaly Aguilera Vasquez; Daiva E Nielsen
Journal:  Curr Nutr Rep       Date:  2022-08-18

5.  A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Authors:  Tiziana Bisogno; Anu Mahadevan; Roberto Coccurello; Jae Won Chang; Marco Allarà; Yugang Chen; Giacomo Giacovazzo; Aron Lichtman; Benjamin Cravatt; Anna Moles; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Authors:  R B Laprairie; A M Bagher; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2015-10-13       Impact factor: 8.739

7.  Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes.

Authors:  Barbara Bosier; Luigi Bellocchio; Mathilde Metna-Laurent; Edgar Soria-Gomez; Isabelle Matias; Etienne Hebert-Chatelain; Astrid Cannich; Marlène Maitre; Thierry Leste-Lasserre; Pierre Cardinal; Juan Mendizabal-Zubiaga; Miren Josune Canduela; Leire Reguero; Emmanuel Hermans; Pedro Grandes; Daniela Cota; Giovanni Marsicano
Journal:  Mol Metab       Date:  2013-08-09       Impact factor: 7.422

8.  Hypothalamic 2-arachidonoylglycerol regulates multistage process of high-fat diet preferences.

Authors:  Sei Higuchi; Keiichi Irie; Ryuji Yamaguchi; Mai Katsuki; Maiko Araki; Makiko Ohji; Kazuhide Hayakawa; Shohei Mishima; Yoshiharu Akitake; Kiyoshi Matsuyama; Kenji Mishima; Kenichi Mishima; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

Review 9.  Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Michihiro Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-08

Review 10.  Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.

Authors:  Md Sahab Uddin; Anna Stachowiak; Abdullah Al Mamun; Nikolay T Tzvetkov; Shinya Takeda; Atanas G Atanasov; Leandro B Bergantin; Mohamed M Abdel-Daim; Adrian M Stankiewicz
Journal:  Front Aging Neurosci       Date:  2018-01-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.